Minerva Neurosciences (NERV) Amortizatization of Intangibles (2014 - 2026)
Minerva Neurosciences (NERV) reported Amortizatization of Intangibles of $136741.0 for Q1 2026, up 3112.14% quarter-over-quarter from $4257.0 in Q3 2024.
Minerva Neurosciences (NERV) Amortizatization of Intangibles (2014 - 2026) Analysis & Trends
Minerva Neurosciences has reported Amortizatization of Intangibles for 12 years, with the latest figure at $136741.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles changed N/A year-over-year to $136741.0; the trailing twelve-month figure through Mar 2026 stood at $136741.0 (up 1184.92% YoY), and the FY2024 full-year result was $17027.0, down 33.33% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $136741.0, up from $4257.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $136741.0 in Q1 2026, with the low at $4257.0 in Q3 2024.
- Historically, Amortizatization of Intangibles has averaged $20632.6 across 4 years, with a median of $6385.0 in 2022.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles changed 0.0% — and 2024, when it plunged 33.33%.
- Minerva Neurosciences' Amortizatization of Intangibles stood at $6385.0 in 2022, then changed by 0.0% to $6385.0 in 2023, then sank by 33.33% to $4257.0 in 2024, then surged by 3112.14% to $136741.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $136741.0 (Q1 2026), $4257.0 (Q3 2024), and $6385.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Minerva Neurosciences | 198.87 Mn | 198.87 Mn | - | 136,741.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 136,741.00 |
| Mar 31, 2026 | 136,741.00 |
| Sep 30, 2024 | 4,257.00 |
| Sep 30, 2024 | 4,257.00 |
| Jun 30, 2024 | 6,385.00 |
| Jun 30, 2024 | 6,385.00 |
| Mar 31, 2024 | 6,385.00 |
| Mar 31, 2024 | 6,385.00 |
| Dec 31, 2023 | 6,385.00 |
| Dec 31, 2023 | 6,385.00 |
| Sep 30, 2023 | 6,385.00 |
| Sep 30, 2023 | 6,385.00 |
| Jun 30, 2023 | 6,385.00 |
| Jun 30, 2023 | 6,385.00 |
| Mar 31, 2023 | 6,385.00 |
| Mar 31, 2023 | 6,385.00 |
| Dec 31, 2022 | 6,385.00 |
| Dec 31, 2022 | 6,385.00 |
| Sep 30, 2021 | 14,939.00 |
| Sep 30, 2021 | 14,939.00 |